JP2023521383A5 - - Google Patents

Info

Publication number
JP2023521383A5
JP2023521383A5 JP2022561542A JP2022561542A JP2023521383A5 JP 2023521383 A5 JP2023521383 A5 JP 2023521383A5 JP 2022561542 A JP2022561542 A JP 2022561542A JP 2022561542 A JP2022561542 A JP 2022561542A JP 2023521383 A5 JP2023521383 A5 JP 2023521383A5
Authority
JP
Japan
Prior art keywords
sequence number
antisense
strand
sense strand
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521383A (ja
JP7839554B2 (ja
Filing date
Publication date
Priority claimed from US16/842,404 external-priority patent/US11180759B2/en
Application filed filed Critical
Priority claimed from PCT/US2021/026147 external-priority patent/WO2021207339A1/en
Publication of JP2023521383A publication Critical patent/JP2023521383A/ja
Publication of JP2023521383A5 publication Critical patent/JP2023521383A5/ja
Priority to JP2026041020A priority Critical patent/JP2026120540A/ja
Application granted granted Critical
Publication of JP7839554B2 publication Critical patent/JP7839554B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561542A 2020-04-07 2021-04-07 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 Active JP7839554B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026041020A JP2026120540A (ja) 2020-04-07 2026-03-13 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/842,404 2020-04-07
US16/842,404 US11180759B2 (en) 2016-01-19 2020-04-07 Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
PCT/US2021/026147 WO2021207339A1 (en) 2020-04-07 2021-04-07 Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026041020A Division JP2026120540A (ja) 2020-04-07 2026-03-13 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Publications (3)

Publication Number Publication Date
JP2023521383A JP2023521383A (ja) 2023-05-24
JP2023521383A5 true JP2023521383A5 (cg-RX-API-DMAC7.html) 2024-04-09
JP7839554B2 JP7839554B2 (ja) 2026-04-02

Family

ID=78024140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561542A Active JP7839554B2 (ja) 2020-04-07 2021-04-07 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物
JP2026041020A Pending JP2026120540A (ja) 2020-04-07 2026-03-13 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026041020A Pending JP2026120540A (ja) 2020-04-07 2026-03-13 Krasの阻害のためのrna干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Country Status (4)

Country Link
EP (1) EP4100530A4 (cg-RX-API-DMAC7.html)
JP (2) JP7839554B2 (cg-RX-API-DMAC7.html)
CA (1) CA3169550A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021207339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149557A4 (en) * 2020-05-13 2025-01-15 The University of North Carolina at Chapel Hill Nucleic acid ligand conjugates and use thereof for delivery to cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190995A2 (en) 2007-09-18 2010-06-02 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
JP6010458B2 (ja) * 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. 非対称二本鎖rnaによる特異的阻害のための、方法および組成物
CN104583406A (zh) * 2012-05-02 2015-04-29 诺华股份有限公司 治疗kras相关疾病的有机组合物
WO2015164818A1 (en) * 2014-04-25 2015-10-29 Strike Bio, Inc. Multiple targeted rnai for the treatment of cancers
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
US10619159B2 (en) * 2016-01-19 2020-04-14 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference for inhibition of KRAS
US10858656B2 (en) * 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
AU2019255765B2 (en) * 2018-04-19 2025-02-06 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes

Similar Documents

Publication Publication Date Title
JP7837560B2 (ja) 安定性の向上を有する修飾オリゴヌクレオチドの合成
JP2025072451A (ja) 安定性が増加した修飾オリゴヌクレオチド
EP2673286B1 (en) Therapeutic compounds
US8513401B2 (en) Double stranded nucleic acid targeting low copy promoter-specific RNA
JP2009536827A5 (cg-RX-API-DMAC7.html)
JP2018512155A5 (cg-RX-API-DMAC7.html)
JP2018512041A5 (cg-RX-API-DMAC7.html)
CN104955950A (zh) 具有改善的脱靶特征谱的寡核苷酸
JP2012050447A (ja) 染色体dnaに標的化されるオリゴマーによる遺伝子発現の調節
CN102281872A (zh) 多价rna纳米颗粒组合物
CN102575252A (zh) 用于多价rna干扰的多核苷酸、组合物及其使用方法
JP2017528441A5 (cg-RX-API-DMAC7.html)
JP2005517436A5 (cg-RX-API-DMAC7.html)
EP2844757A2 (en) Organic compositions to treat kras-related diseases
Ricciardi et al. Targeted genome modification via triple helix formation
Robb et al. Exploiting microRNAs as cancer therapeutics
JP7497061B2 (ja) Rna分子、キメラ型na分子、二本鎖rna分子、および二本鎖キメラ型na分子
JP2007530431A5 (cg-RX-API-DMAC7.html)
JP2024523424A5 (cg-RX-API-DMAC7.html)
EP2135947A1 (en) Antagonists of bacterial sequences
Pérez et al. MicroRNA interference
WO2020251973A1 (en) Compositions and methods for rna interference
WO2020171149A1 (ja) ヘテロ核酸の最適ps修飾パターン
CN116917480A (zh) Rna分子、嵌合体型na分子、双链rna分子及双链嵌合体型na分子
Duong et al. RNA therapeutics for β-thalassemia